Exp Ther Med 21: [Related article:] 25, 2021; DOI:
10.3892/etm.2020.9457
Following the publication of the above article, and
an Expression of concern statement (doi: 10.3892/etm.2026.13319)
that was published after a concerned reader drew to the Editor's
attention that one of the antibodies the authors had used in their
study was apparently selected inappropriately, the authors have now
responded to the Editor's request for information. The antibody
(cat. no. ab51243) that the authors reported to have used in their
paper is specific for the protein known as p16-ARC (or ARPC5), not
the apoptosis-associated protein p16-INK4a, as was intended.
Upon re-examining their reagent records, the authors
can confirm that writing “rabbit anti-p16 (cat. no. ab51243)” on
line 11 of the “Drugs and reagents” subsection of the
Materials and methods on p. 2 of this paper was a typing error. The
actual antibody used in Fig. 4F for the western blot experiments
was Anti-CDKN2A/p16INK4a (cat. no. ab108349). Supporting documents
for the antibody purchase were provided for the inspection of the
Editorial Office.
Therefore, the text in the “Drugs and
reagents” subsection of the Materials and methods on p. 2,
where the reporting of the various antibodies is described, should
have read as follows (the changed text is highlighted in
bold): “Rabbit anti-PCSK9 (cat. no. ab95478), mouse anti-p53
(cat. no. ab26), rabbit anti-p21 (cat. no. ab188224) and rabbit
anti-CDKN2A/p16INK4a (cat . no. ab108349) were purchased
from Abcam.” Note that the error made in reporting the source of
the anti-CDKN2A/p16INK4a antibody did not affect the results or the
overall conclusions reported in the paper. The authors express
their thanks to the Editor of Experimental and Therapeutic
Medicine for allowing them the opportunity to publish this
corrigendum. All the authors agree with the publication of this
corrigendum, and wish to apologize to the readership for any
inconvenience caused.
